Intech Investment Management LLC Buys Shares of 23,003 Replimune Group, Inc. (NASDAQ:REPL)

Intech Investment Management LLC acquired a new stake in Replimune Group, Inc. (NASDAQ:REPL) during the 3rd quarter, HoldingsChannel reports. The firm acquired 23,003 shares of the company’s stock, valued at approximately $252,000.

Several other institutional investors and hedge funds also recently made changes to their positions in REPL. Quest Partners LLC boosted its holdings in shares of Replimune Group by 30.4% in the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after acquiring an additional 3,150 shares during the period. Algert Global LLC lifted its holdings in shares of Replimune Group by 5.4% in the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after acquiring an additional 4,340 shares during the last quarter. Creative Planning lifted its stake in Replimune Group by 28.7% in the third quarter. Creative Planning now owns 21,047 shares of the company’s stock worth $231,000 after purchasing an additional 4,699 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after acquiring an additional 4,946 shares during the period. Finally, Los Angeles Capital Management LLC boosted its stake in shares of Replimune Group by 8.1% during the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock valued at $646,000 after purchasing an additional 5,410 shares during the period. Institutional investors own 92.53% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on REPL shares. HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Replimune Group in a report on Friday, November 22nd. Roth Mkm started coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price on the stock. Roth Capital raised Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Jefferies Financial Group lifted their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. boosted their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Replimune Group currently has a consensus rating of “Buy” and an average target price of $17.29.

Insiders Place Their Bets

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 8.80% of the company’s stock.

Replimune Group Trading Down 0.9 %

REPL stock opened at $13.05 on Friday. The stock has a market capitalization of $892.88 million, a price-to-earnings ratio of -4.28 and a beta of 1.26. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The firm’s fifty day simple moving average is $12.06 and its two-hundred day simple moving average is $10.16. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. As a group, analysts anticipate that Replimune Group, Inc. will post -2.99 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.